PFBT
TRVI icon

Parkside Financial Bank & Trust’s Trevi Therapeutics TRVI Stock Holding History

Parkside Financial Bank & Trust’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Hold
140
– – ﹤0.01% 2090
2026
Q1 		$1.67K Hold
140
– – ﹤0.01% 2183
2025
Q4 		$1.75K Hold
140
– – ﹤0.01% 2150
2025
Q3 		$1.28K Hold
140
– – ﹤0.01% 2184
2025
Q2 		$766 Hold
140
– – ﹤0.01% 2350
2025
Q1 		$880 Buy
+140
New +$668 ﹤0.01% 2156

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Parkside Financial Bank & Trust's TRVI Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 140 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2090.

Parkside Financial Bank & Trust first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Parkside Financial Bank & Trust held 140 shares of Trevi Therapeutics worth $2.61K as of Q2 2026.
  • Parkside Financial Bank & Trust left its Trevi Therapeutics share count unchanged in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2090 holding.
  • Parkside Financial Bank & Trust first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.